Physicians Choice (PhC). clinical trials

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

This study looks at a new treatment, Trastuzumab-Deruxtecan, for some people with early breast cancer that has shown signs of coming back at a molecular level. It compares this new drug to standard treatments to see which works best.